Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) has been assigned an average rating of “Hold” from the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $27.22.
Several brokerages have commented on PCRX. Needham & Company LLC raised their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays lifted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, HC Wainwright lifted their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, February 28th.
Get Our Latest Analysis on Pacira BioSciences
Institutional Inflows and Outflows
Pacira BioSciences Trading Up 0.8 %
PCRX opened at $22.87 on Monday. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.27 and a beta of 0.86. The business has a 50 day simple moving average of $23.96 and a two-hundred day simple moving average of $19.25. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.
About Pacira BioSciences
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Recommended Stories
- Five stocks we like better than Pacira BioSciences
- Find and Profitably Trade Stocks at 52-Week Lows
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- The How and Why of Investing in Gold Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.